>The first 10 subjects will receive Atezolizumab
840 mg IV on Day 1 and Day 15 of each 28-day cycle. Subjects will be treated for 2 cycles before undergoing metastatectomy within 42 days of completion of Cycle 2. No
study treatment is administered while subjects are healing after surgery
>The next 15 subjects will receive Atezolizumab
840 mg IV on Day 1 and Day 15 and Cobimetinib
60 mg PO on Days 1-21 of each 28-day cycle. Cobimetinib
must be held for the 7 days prior to metastatectomy. Subjects will be treated for 2 cycles before undergoing metastatectomy within 42 days of completion of Cycle 2.td><td
1. Histologically and/or cytologically confirmed and radiographically measurable per
RECIST v1.1 colorectal cancer with liver metastasis. Patients may have other sites of
2. Liver lesion safely amenable to core needle biopsy.
3. Willing to undergo core needle biopsy of liver metastatic site.
4. Microsatellite stable disease as determined by IHC and/or PCR.
5. Plan for next therapeutic intervention to be surgical resection of metastatic disease.
6. Age ≥18 years with ability to understand and willingness to provide informed consent.
7. ECOG performance status of 0 or 1.
8. Life expectancy of >3 months.
9. For Combination Therapy cohort only: Able to swallow pills.
10. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test
within 7 days prior to start of study drug and must be willing to use two methods of
contraception, one of them being a barrier method during the study and for 3 months
(or 6 months for subjects on Combination Therapy cohort) after last study drug
11. Adequate organ and marrow function as defined below:
1. Absolute neutrophil count (ANC) ≥1500 µl
2. WBC counts > 2500/µl
3. Lymphocyte count ≥ 300/µl
4. Platelets ≥ 100,000/µl
5. Hemoglobin (Hgb) ≥ 9 g/dL
6. Total bilirubin ≤ 1.5 x upper limit of normal (ULN); ≤ 3 x ULN for patients with
known Gilbert disease
7. AST/ALT ≤ 3 x ULN without liver metastasis; ≤ 5 x ULN for patients with liver
8. Alkaline phosphatase ≤ 2.5 x ULN; ≤ 5 x ULN for patients with liver metastasis
9. Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 ml/min on the basis of
the Cockcroft-Gault glomerular filtration rate estimation
10. INR and aPTT ≤ 1.5 x ULN. Note that this applies only to patients who do not
receive therapeutic anticoagulation; patients receiving therapeutic
anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a
1. Prior therapy with anti-PD-1 or anti-PD-L1 therapeutic antibody or pathway targeting
a. Patients who have received prior treatment with anti-CTLA-4 may be enrolled,
provided the following requirements are met: i. Minimum of 12 weeks from the first
dose of anti-CTLA-4 and > 6 weeks from the last dose.
ii. No history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE
Grade 3 and 4)
2. For Combination Therapy cohort only: Prior therapy with MEK inhibitors.
3. Anticancer therapy, including but not limited to chemotherapy, hormonal therapy, or
radiotherapy, within 4 weeks prior to start of study treatment; however, the following
1. Hormone-replacement therapy or oral contraceptives
2. Herbal therapy > 1 week prior to start of study treatment (herbal therapy
intended as anticancer therapy must be discontinued at least 1 week prior to
start of study treatment)
3. Palliative radiotherapy for bone metastases > 2 weeks prior to start of study
4. Expected to require any other form of systemic or localized anticancer therapy while
5. Adverse events from prior anticancer therapy that have not resolved to Grade ≤ 1
except for alopecia.
6. Investigational agent within 4 weeks prior to start of study treatment (or within five
half-lives of the investigational product, whichever is longer).
7. Major surgical procedure within 28 days prior to start of study treatment or
anticipation of need for a major surgical procedure during the course of the study.
This does not refer to the planned liver metastatectomy that is part of the study.
8. Malignancies other than the disease under study within 5 years prior to start of study
treatment, with the exception of those with a negligible risk of metastasis or death
and with expected curative outcome (such as adequately treated carcinoma in situ of
the cervix, basal or squamous cell skin cancer, localized prostate cancer treated
surgically with curative intent, or ductal carcinoma in situ treated surgically with
curative intent) or undergoing active surveillance per standard-of-care management
(e.g. chronic lymphocytic leukemia Rai stage 0, prostate cancer with Gleason score <
6, and prostate-specific [PSA] ≤ 10 mg/mL, etc).
9. Diagnosis of acute leukemias, accelerated/blast-phase chronic myelogenous leukemia,
chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory
10. Prior allogenic bone marrow transplantation or prior solid organ transplantation.
11. Known primary central nervous system (CNS) malignancy or symptomatic CNS metastases.
a. Patients with asymptomatic untreated CNS disease may be enrolled, provided all of
the following criteria are met: i. Evaluable or measurable disease outside the CNS ii.
No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of
the optic apparatus (optic nerves and chiasm) iii. No history of intracranial
hemorrhage or spinal cord hemorrhage iv. No ongoing requirement for dexamethasone for
CNS disease; patients on a stable dose of anticonvulsants are permitted.
v. No neurosurgical resection or brain biopsy within 28 days prior to start of study
treatment b. Patients with asymptomatic treated CNS metastases may be enrolled,
provided all the criteria listed above are met as well as the following: i.
Radiographic demonstration of improvement upon the completion of CNS-directed therapy
and no evidence of interim progression between the completion of CNS-directed therapy
and the screening radiographic study ii. No stereotactic radiation or whole-brain
radiation within 28 days prior to start of study treatment iii. Screening CNS
radiographic study ≥ 4 weeks from completion of radiotherapy and ≥ 2 weeks from
discontinuation of corticosteroids
12. Serious, non-healing wound, ulcer, or bone fracture.
13. Pregnancy, lactation, or breastfeeding
14. History of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric or humanized antibodies or fusion proteins or Chinese hamster ovary cell
15. History of malabsorption or other condition that would interfere with absorption of
16. Bisphosphonate therapy for symptomatic hypercalcemia. Use of bisphosphonate therapy
for other reasons (e.g., bone metastasis for osteoporosis) is allowed.
17. Known clinically significant liver disease, including active viral, alcoholic, or
other hepatitis; cirrhosis; fatty liver; and inherited liver disease.
18. History or risk of autoimmune disease, including but not limited to systemic lupus
erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis
associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's
syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune
thyroid disease, vasculitis, or glomerulonephritis.
1. Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid
replacement hormone, controlled Type 1 diabetes mellitus on a stable insulin
regimen are eligible.
2. Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with
dermatologic manifestations only (e.g., patients with psoriatic arthritis would
be excluded) are permitted provided that they meet the following conditions:
i. Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular
manifestations ii. Rash must cover less than 10% of the body surface area (BSA) iii.
Disease is well controlled at baseline and only requiring low potency topical steroids
(e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide
0.05%, aclometasone dipropionate 0.05%) iv. No acute exacerbations of underlying
condition within the last 12 months (not requiring psoralen plus ultraviolet A
radiation (PUVA), methotrexate, retinoids, biologic agents, oral calcineurin
inhibitors; high potency or oral steroids)
19. History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced),
organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing
pneumonia, etc.), or evidence of active pneumonitis on screening chest computed
tomography (CT) scan. (History of radiation pneumonitis in the radiation field
(fibrosis) is permitted)
20. Treatment with systemic immunostimulatory agents (including but not limited to
interferon [IFN]-α or interleukin [IL]-2) within 6 weeks or five half-lives of the
drug (whichever is shorter) prior to start of study treatment.
21. Treatment with systemic immunosuppressive medications (including but not limited to
prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor
necrosis factor [anti-TNF] agents) within 2 weeks prior to start of study treatment.
1. Patients who have received acute, low-dose, systemic immunosuppressant
medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled
2. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone)
for patients with orthostatic hypotension or adrenocortical insufficiency is
22. History of HIV infection or active hepatitis B (chronic or acute) or hepatitis C
1. Patients with past or resolved hepatitis B infection (defined as having a
negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc
[antibody to hepatitis B core antigen] antibody test) are eligible.
2. Patients positive for hepatitis C virus (HCV) antibody are eligible only if
polymerase chain reaction (PCR) is negative for HCV RNA.
23. Active tuberculosis
24. Severe infections within 4 weeks prior to start of study treatment, including but not
limited to hospitalization for complications of infection, bacteremia, or severe
25. Signs or symptoms of infection within 2 weeks prior to start of study treatment
26. Received oral or IV antibiotics within 2 weeks prior to start of study treatment
a. Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary
tract infection or chronic obstructive pulmonary disease) are eligible
27. Administration of a live, attenuated vaccine within 4 weeks before start of study
treatment or anticipation that such a live, attenuated vaccine will be required during
a. Influenza vaccination should be given during influenza season only (approximately
October to March). Patients must not receive live, attenuated influenza vaccine (e.g.,
FluMist®) within 4 weeks prior to start of study treatment or at any time during the
28. History of or evidence of retinal pathology on ophthalmologic examination that is
considered a risk factor for neurosensory retinal detachment, retinal vein occlusion
(RVO), or neovascular macular degeneration. Patients should be excluded if they have
the following risk factors for RVO:
1. History of serous retinopathy
2. History of retinal vein occlusion (RVO)
3. Evidence of ongoing serous retinopathy or RVO at baseline
29. History of clinically significant cardiac dysfunction, including the following:
1. Current unstable angina
2. Current symptomatic congestive heart failure of NYHA class 2 or higher
3. Uncontrolled hypertension ≥ Grade 2 (patients with a history of hypertension
controlled with anti-hypertensives to ≤ Grade 1 are eligible).
4. Left ventricular ejection fraction (LVEF) below institutional LLN or below 50%,
whichever is lower
5. Uncontrolled arrhythmias
6. Myocardial infarction, severe/unstable angina, symptomatic congestive heart
failure, cerebrovascular accident or transient ischemic attack within the
previous 6 months
30. Any other diseases, metabolic dysfunction, physical examination finding, or clinical
laboratory finding giving reasonable suspicion of a disease or condition that
contraindicates the use of an investigational drug or that may affect the
interpretation of the results of render the patient at high risk from treatment
31. Inability to comply with study and follow-up procedures.